Evidence map›Paper›PMID 35630302›Full record

ArticleMicroorganisms2022

SARS-CoV-2 Vaccine Alpha and Delta Variant Breakthrough Infections Are Rare and Mild but Can Happen Relatively Early after Vaccination.

Jelissa Katharina Peter, Fanny Wegner, Severin Gsponer, Fabrice Helfenstein, Tim Roloff, Rahel Tarnutzer, Kerstin Grosheintz, Moritz Back, Carla Schaubhut, Sabina Wagner and 18 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04351503 (A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04351503 completednot on this map

A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City

TypeobservationalSponsorUniversity Hospital, Basel, SwitzerlandRan2020 to 2022Enrolled126,586ConditionsSARS Coronavirus (SARS-CoV-2) InfectionArmsStudy A, Study B, Study C, Study D
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Optimizing infectious disease mitigation under dynamic conditions.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 4 institutions in 1 country.

Jelissa Katharina PeterDepartment of Health Basel-City, 4052 Basel, Switzerland.
Fanny WegnerApplied Microbiology Research, Department of Biomedicine, University of Basel, 4056 Basel, Switzerland.
Severin GsponerDepartment of Health Basel-City, 4052 Basel, Switzerland.
Fabrice HelfensteinDepartment of Clinical Research, University Hospital Basel, 4031 Basel, Switzerland.
Tim RoloffApplied Microbiology Research, Department of Biomedicine, University of Basel, 4056 Basel, Switzerland.ORCID 0000-0003-3435-4723
Rahel TarnutzerDepartment of Health Basel-City, 4052 Basel, Switzerland.
Kerstin GrosheintzDepartment of Health Basel-City, 4052 Basel, Switzerland.
Moritz BackDepartment of Health Basel-City, 4052 Basel, Switzerland.
Carla SchaubhutDepartment of Health Basel-City, 4052 Basel, Switzerland.
Sabina WagnerDepartment of Health Basel-City, 4052 Basel, Switzerland.
Helena M B Seth-SmithApplied Microbiology Research, Department of Biomedicine, University of Basel, 4056 Basel, Switzerland.
Patrick ScottonCorona Vaccination Centre for the Canton of Basel-City, 4058 Basel, Switzerland.
Maurice RedondoViollier AG, 4123 Allschwil, Switzerland.
Christiane BeckmannViollier AG, 4123 Allschwil, Switzerland.ORCID 0000-0001-9030-083X
Tanja StadlerDepartment of Biosystems Science and Engineering, ETH Zurich, 4058 Basel, Switzerland.ORCID 0000-0001-6431-535X
Andrea SalzmannViollier AG, 4123 Allschwil, Switzerland.
Henriette KurthViollier AG, 4123 Allschwil, Switzerland.
Karoline LeuzingerClinical Virology, University Hospital Basel, 4031 Basel, Switzerland.
Stefano BassettiInternal Medicine, University Hospital Basel, 4031 Basel, Switzerland.ORCID 0000-0003-1729-1425
Roland BingisserEmergency Medicine, University Hospital Basel, 4031 Basel, Switzerland.
Martin SiegemundIntensive Care Medicine, University Hospital Basel, 4031 Basel, Switzerland.ORCID 0000-0002-2013-4140
Maja WeisserInfectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
Manuel BattegayInfectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
Sarah Tschudin SutterInfectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
Aitana LebrandSIB Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland.
Hans H HirschViollier AG, 4123 Allschwil, Switzerland.
Simon FuchsDepartment of Health Basel-City, 4052 Basel, Switzerland.ORCID 0000-0002-3553-629X
Adrian EgliApplied Microbiology Research, Department of Biomedicine, University of Basel, 4056 Basel, Switzerland.ORCID 0000-0002-3564-8603
University of Basel · CHSIB Swiss Institute of Bioinformatics · CHUniversity Hospital of Basel · CHETH Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: Some COVID-19 vaccine recipients show breakthrough infection. It remains unknown, which factors contribute to risks and severe outcomes. Our aim was to identify risk factors for SCoV2 breakthrough infections in fully vaccinated individuals. (2) Methods: We conducted a retrospective case-control study from 28 December 2020 to 25 October 2021. Data of all patients with breakthrough infection was compared to data of all vaccine recipients in the Canton of Basel-City, Switzerland. Further, breakthrough infections by Alpha- and Delta-variants were compared. (3) Results: Only 0.39% (488/126,586) of all vaccine recipients suffered from a breakthrough infection during the observational period, whereof most cases were asymptomatic or mild (97.2%). Breakthrough infections after full vaccination occurred in the median after 78 days (IQR 47-123.5). Factors with lower odds for breakthrough infection were age (OR 0.987) and previous COVID-19 infection prior to vaccination (OR 0.296). Factors with higher odds for breakthrough infection included vaccination with Pfizer/BioNTech instead of Moderna (OR 1.459), chronic disease (OR 2.109), and healthcare workers (OR 1.404). (4) Conclusions: Breakthrough infections are rare and mild but can occur early after vaccination. This implies that booster vaccination might be initiated earlier, especially for risk groups. Due to new variants emerging repeatedly, continuous monitoring of breakthrough infections is crucial.

Indexed as

Alphabreakthrough infectionCOVID-19COVID-19 vaccineDeltaModernaPfizer/BioNTechSARS-CoV-2

Identifiers

PMID35630302
PMCPMC9146960
OpenAlexW4224239537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.